Cardiovascular disease in peritoneal dialysis

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Cardiovascular morbidity and mortality rates are notably high in patients with end-stage renal disease (ESRD).
• Lipid abnormalities may present differently and hold greater significance in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) compared to hemodialysis.
• Vessel calcification is a suspected contributor to atherosclerotic heart disease in ESRD, though its precise role as a risk factor requires further elucidation.

Purpose of the Study:

• To review the cardiovascular complications in ESRD patients.
• To highlight the significance of lipid abnormalities in CAPD.
• To discuss left ventricular hypertrophy (LVH) and its management, as well as a specific hemodialysis-associated cardiac syndrome.

Main Methods:

• Review of clinical observations and existing literature on cardiovascular issues in ESRD.
• Analysis of the role of lipid abnormalities in different dialysis modalities.
• Examination of factors contributing to and managing left ventricular hypertrophy.
• Description of a specific hemodialysis heart syndrome.

Main Results:

• Left ventricular hypertrophy (LVH) is prevalent in ESRD patients, correlating with distinct clinical presentations and elevated mortality risk.
• Effective management of anemia with erythropoietin and stringent blood pressure control can lead to regression of severe LVH.
• A distinct syndrome of hypertrophic, high cardiac output hemodialysis heart is identified, associated with LVH and potential right ventricular hypertrophy.

Conclusions:

• Cardiovascular health is critical in ESRD management, with specific considerations for dialysis modalities.
• Therapeutic strategies targeting anemia and hypertension show promise in mitigating cardiac remodeling.
• The identified hemodialysis heart syndrome may necessitate interventions such as fistula revision or a transition to peritoneal dialysis.